Supplementary Results from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development
Nallasivam Palanisamy(Henry Ford Health System), Nora M. Navone(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Elsa M. Li-Ning-Tapia(The University of Texas MD Anderson Cancer Center), Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Jun Yang(Sir Run Run Shaw Hospital), Louis L. Pisters(The University of Texas MD Anderson Cancer Center), John C. Araujo(The University of Texas MD Anderson Cancer Center), Estefanía Labanca(The University of Texas MD Anderson Cancer Center), Vikas Kundra(The University of Texas MD Anderson Cancer Center), Scott A. Tomlins(Stratasys (Israel)), Elba S. Vázquez(Fundación Ciencias Exactas y Naturales), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Xuemei Wang(The University of Texas MD Anderson Cancer Center), Murali K. Ravoori(The University of Texas MD Anderson Cancer Center), Shannon L. Carskadon(Henry Ford Health System), Lakshmi P. Kunju(University of Michigan), Peter D.A. Shepherd(The University of Texas MD Anderson Cancer Center), Xinhai Wan(The University of Texas MD Anderson Cancer Center), Arul M. Chinnaiyan(University of Michigan)
Cited by 0
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k